IBDEI0RL ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12421,1,4,0)
 ;;=4^E11.311
 ;;^UTILITY(U,$J,358.3,12421,2)
 ;;=^5002632
 ;;^UTILITY(U,$J,358.3,12422,0)
 ;;=E11.319^^49^600^22
 ;;^UTILITY(U,$J,358.3,12422,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12422,1,3,0)
 ;;=3^DM Type 2 w/ Unspec Diabetic Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,12422,1,4,0)
 ;;=4^E11.319
 ;;^UTILITY(U,$J,358.3,12422,2)
 ;;=^5002633
 ;;^UTILITY(U,$J,358.3,12423,0)
 ;;=E11.40^^49^600^11
 ;;^UTILITY(U,$J,358.3,12423,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12423,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,12423,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,12423,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,12424,0)
 ;;=E11.41^^49^600^10
 ;;^UTILITY(U,$J,358.3,12424,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12424,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Mononeuropathy
 ;;^UTILITY(U,$J,358.3,12424,1,4,0)
 ;;=4^E11.41
 ;;^UTILITY(U,$J,358.3,12424,2)
 ;;=^5002645
 ;;^UTILITY(U,$J,358.3,12425,0)
 ;;=E11.42^^49^600^14
 ;;^UTILITY(U,$J,358.3,12425,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12425,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,12425,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,12425,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,12426,0)
 ;;=E11.43^^49^600^8
 ;;^UTILITY(U,$J,358.3,12426,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12426,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,12426,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,12426,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,12427,0)
 ;;=E11.51^^49^600^12
 ;;^UTILITY(U,$J,358.3,12427,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12427,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Peripheral Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,12427,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,12427,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,12428,0)
 ;;=E11.52^^49^600^13
 ;;^UTILITY(U,$J,358.3,12428,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12428,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,12428,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,12428,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,12429,0)
 ;;=E11.621^^49^600^15
 ;;^UTILITY(U,$J,358.3,12429,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12429,1,3,0)
 ;;=3^DM Type 2 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,12429,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,12429,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,12430,0)
 ;;=E11.641^^49^600^17
 ;;^UTILITY(U,$J,358.3,12430,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12430,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/ Coma
 ;;^UTILITY(U,$J,358.3,12430,1,4,0)
 ;;=4^E11.641
 ;;^UTILITY(U,$J,358.3,12430,2)
 ;;=^5002661
 ;;^UTILITY(U,$J,358.3,12431,0)
 ;;=E11.649^^49^600^18
 ;;^UTILITY(U,$J,358.3,12431,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12431,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,12431,1,4,0)
 ;;=4^E11.649
 ;;^UTILITY(U,$J,358.3,12431,2)
 ;;=^5002662
 ;;^UTILITY(U,$J,358.3,12432,0)
 ;;=E78.01^^49^600^24
 ;;^UTILITY(U,$J,358.3,12432,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12432,1,3,0)
 ;;=3^Familial Hypercholesterolemia
 ;;^UTILITY(U,$J,358.3,12432,1,4,0)
 ;;=4^E78.01
 ;;^UTILITY(U,$J,358.3,12432,2)
 ;;=^7570555
 ;;^UTILITY(U,$J,358.3,12433,0)
 ;;=E78.00^^49^600^33
 ;;^UTILITY(U,$J,358.3,12433,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12433,1,3,0)
 ;;=3^Pure Hypercholesterolemia,Unspec
